Study 8 of 8Abaloparatide (Tymlos) literatureNatureTop journal2026
De novo design of miniproteins targeting GPCRs.
Not reported in abstract.
Where it sits
this study against the rest of the abaloparatide (tymlos) corpus1
Preclinical · this one
4
Observational
0
Open-label
0
Randomised
3
Reviews
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2026
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.
Elsewhere in the Abaloparatide (Tymlos) corpus
CComparable Initial Engagement of Intracellular Signaling Pathways by Parathyroid Hormone Receptor Ligands Teriparatide, Abaloparatide, and Long-Acting PTH.JBMR plus · 2021 · Not reported in abstract.In vitroBParathyroid hormone receptor agonists in the management of osteoporosis.Nature reviews. Rheumatology · 2025 · Not reported in abstract.HumanBBone Optimization for Perioperative Spine Patients: A Multidisciplinary Approach at a Single Academic Center.europepmc · 2025 · 60% demonstrated improved bone mineral density, with an average T-score gain of 0.6 ± 0.5.HumanDIndividualized Fracture Prevention for Postmenopausal Women with Osteopenia.europepmc · 2025 · Not reported in abstract.reviewBReal-world evidence indicates romosozumab use is associated with a greater reduction in osteoporotic fractures than PTH (1-34) analogs in women.europepmc · 2026 · HR for osteoporotic fractures in ROMO users vs PTH receptor agonists: 0.711, 95% CI: 0.542-0.931.HumanBNovel 360° lumbar arthroplasty: Surgical technique and procedural details.europepmc · 2026 · Total VAS score decreased by 9 points (89% reduction), n=24.Human